Table 1

Baseline characteristics and demographics

Oral semaglutide 3 mg (n = 175)Oral semaglutide 7 mg (n = 175)Oral semaglutide 14 mg (n = 175)Placebo (n = 178)Total (N = 703)
Men, n (%)89 (50.9)93 (53.1)86 (49.1)89 (50.0)357 (50.8)
Age, years55 ± 1156 ± 1154 ± 1154 ± 1155 ± 11
Race, n (%)
 White135 (77.1)131 (74.9)130 (74.3)132 (74.2)528 (75.1)
 Black or African American6 (3.4)11 (6.3)10 (5.7)10 (5.6)37 (5.3)
 Asian31 (17.7)30 (17.1)29 (16.6)31 (17.4)121 (17.2)
 Other3 (1.7)3 (1.7)6 (3.4)5 (2.8)17 (2.4)
Hispanic or Latino ethnicity, n (%)52 (29.7)31 (17.7)46 (26.3)51 (28.7)180 (25.6)
Diabetes duration, years3.8 ± 5.33.6 ± 5.13.4 ± 4.43.4 ± 4.63.5 ± 4.9
Body weight, kg86.9 ± 21.089.0 ± 21.888.1 ± 22.188.6 ± 23.488.1 ± 22.1
BMI, kg/m231.8 ± 6.331.6 ± 6.431.7 ± 6.632.2 ± 6.931.8 ± 6.6
HbA1c, %7.9 ± 0.78.0 ± 0.68.0 ± 0.77.9 ± 0.78.0 ± 0.7
HbA1c, mmol/mol63 ± 864 ± 764 ± 863 ± 763 ± 8
Fasting plasma glucose, mg/dL158 ± 42162 ± 42158 ± 39160 ± 39160 ± 41
Fasting plasma glucose, mmol/L8.78 ± 2.358.98 ± 2.348.77 ± 2.178.88 ± 2.168.85 ± 2.25
Estimated glomerular filtration rate, mL/min/1.73 m2*99 ± 1495 ± 1697 ± 16100 ± 1598 ± 15
  • Data are means ± SD unless otherwise indicated.

  • *Glomerular filtration rate was estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.